Serum institute of india pvt. ltd, Company

By Priyanka SharmaNew Delhi, [India], Aug 3 India's top drug regulator-- Drugs Controller General of India (DCGI) has granted permission to Serum Institute of India (SII) to conduct phase 2 and 3 human clinical trials in India on the potential COVID19 vaccine, a senior government official said."After a thorough evaluation, the DCGI has given approval to SII to perform phase-II, III clinical trial based on the recommendations of the Subject Expert Committee (SEC)," the official source told ."As a rapid regulatory response, the proposal was deliberated in the SEC through a virtual meeting earlier this week. And after considering the data generated on the vaccine in phase-1, 2 of the Oxford University trial, the committee recommended granting permission to conduct phase 2, 3 clinical trials of COVISHIELD (SII-ChAdOx1 nCoV-19) healthy adult subjects at risk in the country," the official said.As per the study design, each subject will be administered two doses 4 weeks apart (First dose on Day 1 and Second dose on Day 29) following which the safety and immunogenicity will be assessed at predefined intervals, the official said.According to the official, the pharma firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the Central Drugs Standard Control Orgzation (CDSCO) before it can proceed to phase-3 of the clinical trial.Last week had reported that the domestic pharma giant had made an application to DCGI for grant of permission to conduct phase 2, 3 clinical trials of coronavirus vaccine (ChAdOxlnCoV- 19) in India.The vaccine was manufactured by Serum in India under technical collaboration with Oxford University/Astra Zeneca and is called as COVISHIELD (SII-ChAdOx1 nCoV-19).Currently, phase 2, 3 clinical trials of the Oxford sponsor vaccine is ongoing in United Kingdom, phase 3 clinical trial in Brazil and phase 1, 2 clinical trials in South Africa.It is pertinent to note that COVISHIELD (SII-ChAdOx1 nCoV-19) vaccine contains the replication-deficient simian adenovirus vector ChAdOx1, containing the structural surface glycoprotein (Spike protein) antigens of SARS-CoV-2.( With inputs from ANI )

Serum Institute Of India Pvt. LtdFOLLOW

Serum institute of india pvt. ltd, Latest News

New York, Aug 28 India is on course to have an "approved" vaccine within the first quarter of ... ...

The domestic pharma giants on Monday presented the current status of various candidate vaccines for COVID-19 to the central government. ...

New Delhi, Aug 7 The Serum Institute of India would introduce candidate vaccines from AstraZeneca and Novavax for ... ...

The Serum Institute of India (SII) has entered into a new landmark partnership with Gavi, the Vaccine Alliance and the Bill and Melinda Gates Foundation, to accelerate the manufacture and delivery of up to 100 million doses of COVID-19 vaccines for I ...

The The Drugs Controller General of India (DCGI) gave approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India, said the Ministry of Health and Family ...

New Delhi, Aug 3 The Drugs Controller General of India (DCGI) has given approval to Pune's Serum Institute of ... ...

TVS Motor Company registered a sales growth of 27 per cent in July 2020 with 252,744 units as against 198,387 units in June 2020. ...

By Priyanka Sharma New Delhi, [India], Aug 3 India's top drug regulator-- Drugs Controller General of India (DCGI) ... ...